P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (23rd June 2022)

Record Type:
Journal Article
Title:
P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (23rd June 2022)
Main Title:
P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Authors:
Nastoupil, L.
Morschhauser, F.
Scholz, C. W.
Bishton, M.
Yoon, S.-S.
Giri, P.
Wei, M. C.
Knapp, A.
Li, C.-C.
Bottos, A.
Li, H.
Purev, E.
Bartlett, N. L.
Abstract:
Is Part Of:
HemaSphere. Volume 6(2022)Supplement 3
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Issue Display:
Volume 6, Issue 3 (2022)
Year:
2022
Volume:
6
Issue:
3
Issue Sort Value:
2022-0006-0003-0000
Page Start:
1015
Page End:
1016
Publication Date:
2022-06-23
Subjects:
Hematology -- Periodicals
616.15005
Journal URLs:
https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:
10.1097/01.HS9.0000847368.92731.fb ↗
Languages:
English
ISSNs:
2572-9241
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
22737.xml